The EMSO congress held in Paris, France, and virtually from 9th-13th, September, 2022, was a place to build strong, meaningful academic relationships with colleagues and peers in the field of lung cancer while concomitantly enabling an environment for sharing clinical cases and debates aiming at providing better care for patients. This issue of memo inOncology on lung cancer summarizes treatment benefits and outcome determinants in (neo)adjuvant trials, devotes to new ways to further improve patient outcomes by targeting KRASG12C, EGFR, HER2 and angiogenesis in the first and later lines and highlights the updates on immunotherapy-based treatment of stage III/IV disease. Last but not least, this issue looks closely at air-pollution-induced lung cancer and the benefits of lung cancer mass screening in China.

As an additional feature, you will find expert video interviews with Gérard Zalcman, Marina C. Garassino and Noemi Reguart on different conference highlights on our website.

Download the report, or visit memo inOncology

Access anarticle directly (English):

Preface

Treatment benefits and outcome determinants in (neo)adjuvant trials

Targeted approaches in the first and later lines: KRASG12C, EGFR, HER2 & angiogenesi

Updates on  immunotherapy-based treatment of stage III/IV disease

Air-pollution–induced lung cancer: defining a targetable link

Benefits of lung cancer mass screening in China

Full Report (English)

Slide kit (English)